EBS
Emergent BioSolutions Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$6.21
−0.72%Year over year
Reported trailing growth
- Revenue
- -17.7%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- +1212.3%
Forward estimates
Based on analyst estimates
- Revenue
- +13.0%
- EBITDA
- +268.2%
- EPS
- +110.5%
Three-year CAGR
- Revenue
- -12.7%
- EBITDA
- +91.3%
- EBIT
- +201.4%
- Net income
- +127.6%
- EPS
- +127.2%
- Free cash flow
- +338.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Sep 1, 2026